Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455167 · ClinicalTrials.gov registry record · Phase 3
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
A Phase 3 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT02455167: Clinical Trial Phase 3 study, sponsored by University of Colorado, Denver.
NCT02455167 is a Phase 3 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 9 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02455167, a Phase 3 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV). 2. Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT.
Primary Outcome
Number of participants who cleared Hepatitis C (HCV) after 12 weeks was collected (HCV RNA level was "Not Detected".
Interventions
- DRUG Ribavirin (RBV)
- DRUG Sofosbuvir (SOF)
- DRUG Simeprivir (SMV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-07-18 |
| Phase | Phase 3 |
Why NCT02455167 stopped before completion
NCT02455167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Ribavirin (RBV) is the first listed.
NCT02455167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02455167 about?
NCT02455167 is a clinical study titled "Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis". 1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV). 2. Hepatic improvement during and after Simeprevir(SMV)/Sofos...
What is the current status of trial NCT02455167?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2015-05. Estimated completion is 2016-07-18.
What interventions are being tested in trial NCT02455167?
The interventions under investigation include: Ribavirin (RBV) (DRUG), Sofosbuvir (SOF) (DRUG), Simeprivir (SMV) (DRUG).
Who is sponsoring clinical trial NCT02455167?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02455167's enrollment target sits among peer trials
9 1992nd of 2000 higher than 8 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia